Please ensure Javascript is enabled for purposes of website accessibility

Why Pacira BioSciences Is Soaring Today

By Prosper Junior Bakiny – Jun 29, 2020 at 12:58PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Thanks to a recent FDA decision, its best-selling product, Exparel, will go at least a little longer without facing competition from Heron Therapeutics' HTX-011.

What happened?

Shares of Pacira BioSciences (PCRX 1.57%) are soaring on Monday and are up by 17.5% as of 12:10 p.m. EDT, and this despite the company not reporting any news. We can attribute Pacira's good fortune to one of its potential competitors in the market for postoperative pain, Heron Therapeutics (HRTX 1.34%), failing to earn approval from the U.S. Food and Drug Administration (FDA) for its lead pipeline candidate, HTX-011. 

So what

Heron Therapeutics announced that it had received a complete response letter (CRL) from the FDA regarding its New Drug Application (NDA) for HTX-011. The health industry regulator did not have any concerns with HTX-011's safety or efficacy, but it rejected the drug's application and requested more information from the company regarding several "nonclinical issues." Heron expects this setback to be little more than a temporary hiccup: The company still believes that HTX-011 will earn FDA approval.

Man on a ladder drawing an upward-pointing graph on a blackboard

Image source: Getty Images.

However, the immediate approval of HTX-011 would have meant competition for Pacira BioSciences' Exparel, since both HTX-011 and Exparel are nonopioid medications used to treat postoperative pain. With HTX-011 failing to receive the green light from health industry regulators, it isn't surprising that investors rushed to load up on shares of Pacira BioSciences, thus sending its stock price higher. Meanwhile, Heron Therapeutics is having a bad day on the market today, with its shares down by more than 20% as of midday trading. 

Now what 

During the first quarter, Exparel's revenue came in at $101.3 million, an 11.8% year-over-year increase. Exparel's revenue will likely continue to grow, especially given the FDA's decision to reject Heron's application for HTX-011 as a treatment for postoperative pain. But if Heron Therapeutics ends up earning FDA approval for HTX-011 after all, Pacira BioSciences' stock will come crashing down. Investors will want to keep an eye on both of these healthcare stocks in the coming months. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pacira BioSciences Stock Quote
Pacira BioSciences
$57.45 (1.57%) $0.89
Heron Therapeutics Stock Quote
Heron Therapeutics
$4.53 (1.34%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.